An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Pulm Pharmacol Ther
; 79: 102201, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-36841351
Full text:
1
Database:
MEDLINE
Main subject:
Phosphatidylinositol 3-Kinases
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Pulm Pharmacol Ther
Journal subject:
FARMACOLOGIA
Year:
2023
Type:
Article